D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$862M |
| 2 |
Baidu
BIDU
|
+$752M |
| 3 |
Tencent Music
TME
|
+$426M |
| 4 |
Coca-Cola
KO
|
+$424M |
| 5 |
NVIDIA
NVDA
|
+$383M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$981M |
| 2 |
Wells Fargo
WFC
|
+$673M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$574M |
| 4 |
Moderna
MRNA
|
+$442M |
| 5 |
DuPont de Nemours
DD
|
+$415M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.93% |
| 2 | Consumer Discretionary | 10.48% |
| 3 | Healthcare | 8.56% |
| 4 | Communication Services | 8.41% |
| 5 | Financials | 6.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3326
CALL
MidCap Financial Investment
MFIC
$784M
| $549K | ﹤0.01% |
+40,000
| New | +$528K |
|
|
ZNTEW
3327
DELISTED
Zanite Acquisition Corp. Warrant
ZNTEW
| $549K | ﹤0.01% |
+435,723
| New | +$1.09M |
|
3328
Prelude Therapeutics
PRLD
$305M
| $544K | ﹤0.01% |
+12,546
| New | +$832K |
|
3329
CALL
Green Plains
GPRE
$1.19B
| $541K | ﹤0.01% |
20,000
+2,300
| +13% | +$52.7K |
|
3330
Monro
MNRO
$525M
| $539K | ﹤0.01% |
8,187
-37,697
| -82% | -$2.36M |
|
3331
CALL
TAL Education Group
TAL
$5.71B
| $539K | ﹤0.01% |
10,000
-86,500
| -90% | -$6.33M |
|
3332
Dell
DELL
$283B
| $538K | ﹤0.01% |
12,041
-371,248
| -97% | -$15.2M |
|
3333
The RMR Group
RMR
$342M
| $538K | ﹤0.01% |
13,177
-12,537
| -49% | -$495K |
|
|
DISH
3334
PUT
DELISTED
DISH Network Corp.
DISH
| $536K | ﹤0.01% |
+14,800
| New | +$493K |
|
3335
Great Southern Bancorp
GSBC
$863M
| $535K | ﹤0.01% |
9,446
-7,273
| -44% | -$388K |
|
3336
Terex
TEX
$7.98B
| $535K | ﹤0.01% |
11,602
-20,269
| -64% | -$831K |
|
|
QIWI
3337
PUT
DELISTED
QIWI PLC
QIWI
| $533K | ﹤0.01% |
+50,000
| New | +$536K |
|
3338
Idexx Laboratories
IDXX
$42.9B
| $532K | ﹤0.01% |
1,088
+636
| +141% | +$319K |
|
|
ACRE
3339
Ares Commercial Real Estate
ACRE
$252M
| $531K | ﹤0.01% |
38,691
+25,119
| +185% | +$328K |
|
|
PBPB
3340
DELISTED
Potbelly
PBPB
| $526K | ﹤0.01% |
89,073
-1,219
| -1% | -$6.53K |
|
3341
Robert Half
RHI
$3.61B
| $523K | ﹤0.01% |
6,695
-23,113
| -78% | -$1.68M |
|
|
WBA
3342
DELISTED
Walgreens Boots Alliance
WBA
| $523K | ﹤0.01% |
9,528
-69,019
| -88% | -$3.41M |
|
|
ACAHU
3343
DELISTED
Atlantic Coastal Acquisition Corp. Unit
ACAHU
| $523K | ﹤0.01% |
+53,058
| New | +$528K |
|
3344
PUT
CryoPort
CYRX
$775M
| $520K | ﹤0.01% |
10,000
| – | – |
|
3345
PUT
APA Corp
APA
$12.8B
| $519K | ﹤0.01% |
+29,000
| New | +$529K |
|
3346
Q32 Bio
QTTB
$450M
| $519K | ﹤0.01% |
3,067
+824
| +37% | +$174K |
|
|
EVBG
3347
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $519K | ﹤0.01% |
4,281
-24,215
| -85% | -$3.4M |
|
|
RDS.B
3348
CALL
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $519K | ﹤0.01% |
14,100
+4,000
| +40% | +$153K |
|
|
MAAC
3349
DELISTED
Montes Archimedes Acquisition Corp. Class A Common Stock
MAAC
| $516K | ﹤0.01% |
+52,724
| New | +$535K |
|
3350
Astrana Health
ASTH
$2B
| $515K | ﹤0.01% |
19,019
+7,430
| +64% | +$179K |
|
Similar funds
D.E. Shaw & Co's Q1 2021 Portfolio in Review
As of Q1 2021, D.E. Shaw & Co held 4,712 positions worth $104B, down 7.4% from $112B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
D.E. Shaw & Co withdrew a net $18.3B in Q1 2021, closing 730 positions and reducing 1,773 holdings. Its most notable exit was AstraZeneca, an estimated $214M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, D.E. Shaw & Co opened a new position in Baidu worth $627M.
- D.E. Shaw & Co's largest Q1 2021 buy was Baidu: 2,881,724 shares worth $627M.
- D.E. Shaw & Co added most to Tesla in Q1 2021, an estimated $862M increase.
- D.E. Shaw & Co's biggest Q1 2021 reduction was Amazon, cutting an estimated $981M.
- D.E. Shaw & Co fully exited AstraZeneca in Q1 2021, selling an estimated $214M.
- D.E. Shaw & Co's ten largest holdings make up 9.9% of its $104B portfolio in Q1 2021.
- D.E. Shaw & Co opened 825 new positions and closed 730 in Q1 2021.
- D.E. Shaw & Co's portfolio value fell 7.4% quarter-over-quarter to $104B.
Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.